Misplaced Pages

This is an old revision of this page, as edited by Mo18ekula (talk | contribs) at 14:27, 19 December 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Mcn 5707

Identifiers
IUPAC name (6R,10bR)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrroloisoquinoline
CAS Number	96795-88-9
PubChem CID	126059
ChemSpider	112085
CompTox Dashboard (EPA)	DTXSID20914317
Chemical and physical data
Formula	C18H18ClN
Molar mass	283.80 g·mol
3D model (JSmol)	Interactive image
SMILES C1C2C3=CC=CC=C3(CN2C1)C4=CC=CC=C4Cl
InChI InChI=1S/C18H18ClN/c19-17-9-4-3-7-14(17)16-12-20-11-5-10-18(20)15-8-2-1-6-13(15)16/h1-4,6-9,16,18H,5,10-12H2/t16-,18-/m1/s1 Key:KWMNBUDYCCTHHL-SJLPKXTDSA-N

Mcn 5707 is a SNDRI agent designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980’s.

The Ki numbers quoted (24b) are: DAT 35.9nM, NET: 1.9nM and SERT = 8.5nM.

ChemDrug Ref:

For related agents, see JNJ-7925476, McN 4612-z, McN-5292, McN-5558 & McN5652.

References

1. Maryanoff, B. E., Shank, R. P., Gardocki, J. F. (1986). "McN-5707 and McN-5652-Z". Drugs of the Future. 11 (1): 18. doi:10.1358/dof.1986.011.01.51629.
2. Maryanoff, BE; et al.; Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J Med Chem 1984, 27, 8, 943.
3. Bruce E. Maryanoff, US4719216 (1988 to Janssen Pharmaceuticals Inc).

References

• Serotonin–norepinephrine–dopamine reuptake inhibitors
• Stimulants
• Pyrroloisoquinolines
• Drugs developed by Johnson & Johnson
• Abandoned drugs